VRTX
Vertex Pharmaceuticals insider trading
Health Care · Heavy selling
Close · Oct 5, 2026
$503.50
+25.0% over 12 months
Share price and insider trades
VRTX closeInsider buyInsider sale
Bought, 12 months$0
Sold, 12 months$158M
Insiders buying0
Insiders selling13
Valuation, profit and volume
P/E (trailing)n/aSector median 24.5
Market value—
Profit margin—Revenue growth —
Volume vs. 50-day0.8×Last 5 sessions
Insiders' paper profit—On all tracked purchases —
Summary
Over the past 12 months, 0 Vertex Pharmaceuticals insiders reported open-market purchases totaling $0, while 13 insiders reported sales totaling $158M. 93 of 93 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.
Insider transactions
Open-market purchases and sales. 97 grants, option exercises and tax withholdings are not shown.
| Filed | Insider | Type | Shares | Price | Value | Since | Score |
|---|---|---|---|---|---|---|---|
| Jul 7SEC | Duncan MckechnieEvp, Chief Commercial Officer | Sell Plan | 1,541 | $519.00 | $800K | -3.0% | — |
| Jul 7SEC | Ourania TatsisEvp, Chief Reg. & Quality Off. | Sell Plan | 1,500 | $524.99 | $787K | -4.1% | — |
| Jul 6SEC | Joy LiuGeneral Counsel | Sell Plan | 828 | $502.71 | $416K | +0.2% | — |
| Jun 30SEC | Carmen BozicEvp And Cmo | Sell Plan | 596 | $482.50 | $288K | +4.4% | — |
| Jun 23SEC | Carmen BozicEvp And Cmo | Sell Plan | 1,020 | $462.17 | $471K | +8.9% | — |
| Jun 17SEC | Carmen BozicEvp And Cmo | Sell Plan | 4,062 | $450.00 | $1.8M | +11.9% | — |
| Jun 9SEC | Carmen BozicEvp And Cmo | Sell Plan | 1,745 | $450.00 | $785K | +11.9% | — |
| Jun 3SEC | Joy LiuGeneral Counsel | Sell Plan | 828 | $439.91 | $364K | +14.5% | — |
| Jun 2SEC | Carmen BozicEvp And Cmo | Sell Plan | 1,974 | $450.00 | $888K | +11.9% | — |
| May 19SEC | Carmen BozicEvp And Cmo | Sell Plan | 1,354 | $453.45 | $614K | +11.0% | — |
| May 19SEC | Mark E. BunnageEvp, Chief Scientific Officer | Sell Plan | 33 | $453.45 | $15K | +11.0% | — |
| May 14SEC | Carmen BozicEvp And Cmo | Sell Plan | 6,988 | $450.00 | $3.1M | +11.9% | — |
| May 5SEC | Joy LiuGeneral Counsel | Sell Plan | 1,104 | $425.02 | $469K | +18.5% | — |
| May 5SEC | Sangeeta N. BhatiaDirector | Sell Plan | 318 | $423.73 | $135K | +18.8% | — |
| Apr 3SEC | Joy LiuGeneral Counsel | Sell Plan | 978 | $449.17 | $439K | +12.1% | — |
| Mar 31SEC | Carmen BozicEvp And Cmo | Sell Plan | 2,329 | $450.95 | $1.1M | +11.7% | — |
| Mar 17SEC | Carmen BozicEvp And Cmo | Sell Plan | 2,329 | $481.79 | $1.1M | +4.5% | — |
| Mar 13SEC | Duncan MckechnieEvp, Chief Commercial Officer | Sell Plan | 2,633 | $498.42 | $1.3M | +1.0% | — |
| Mar 6SEC | Duncan MckechnieEvp, Chief Commercial Officer | Sell Plan | 2,437 | $475.30 | $1.2M | +5.9% | — |
| Mar 4SEC | Joy LiuGeneral Counsel | Sell Plan | 892 | $495.96 | $442K | +1.5% | — |
| Mar 3SEC | Reshma KewalramaniCEO, President | Sell Plan | 15,580 | $495.38 | $7.7M | +1.6% | — |
| Mar 3SEC | Reshma KewalramaniCEO, President | Sell Plan | 5,995 | $496.16 | $3.0M | +1.5% | — |
| Mar 3SEC | Reshma KewalramaniCEO, President | Sell Plan | 3,498 | $494.33 | $1.7M | +1.9% | — |
| Mar 3SEC | Reshma KewalramaniCEO, President | Sell Plan | 3,278 | $488.27 | $1.6M | +3.1% | — |
| Mar 3SEC | Reshma KewalramaniCEO, President | Sell Plan | 2,725 | $490.54 | $1.3M | +2.6% | — |
| Mar 3SEC | Reshma KewalramaniCEO, President | Sell Plan | 2,520 | $493.29 | $1.2M | +2.1% | — |
| Mar 3SEC | Reshma KewalramaniCEO, President | Sell Plan | 2,510 | $487.13 | $1.2M | +3.4% | — |
| Mar 3SEC | Carmen BozicEvp And Cmo | Sell Plan | 2,329 | $480.31 | $1.1M | +4.8% | — |
| Mar 3SEC | Reshma KewalramaniCEO, President | Sell Plan | 1,725 | $496.95 | $857K | +1.3% | — |
| Mar 3SEC | Reshma KewalramaniCEO, President | Sell Plan | 949 | $491.30 | $466K | +2.5% | — |
| Mar 3SEC | Reshma KewalramaniCEO, President | Sell Plan | 460 | $489.32 | $225K | +2.9% | — |
| Mar 3SEC | Reshma KewalramaniCEO, President | Sell Plan | 400 | $479.75 | $192K | +5.0% | — |
| Mar 3SEC | Reshma KewalramaniCEO, President | Sell Plan | 240 | $482.84 | $116K | +4.3% | — |
| Mar 3SEC | Reshma KewalramaniCEO, President | Sell Plan | 120 | $481.50 | $58K | +4.6% | — |
| Mar 2SEC | Kristen AmbroseSvp & Chief Accounting Officer | Sell Plan | 357 | $483.36 | $173K | +4.2% | — |
| Feb 26SEC | Duncan MckechnieEvp, Chief Commercial Officer | Sell Plan | 2,500 | $486.35 | $1.2M | +3.5% | — |
| Feb 26SEC | Duncan MckechnieEvp, Chief Commercial Officer | Sell Plan | 2,410 | $489.00 | $1.2M | +3.0% | — |
| Feb 26SEC | Amit SachdevEvp Chief Patient & Ext Af Off | Sell Plan | 1,846 | $486.35 | $898K | +3.5% | — |
| Feb 26SEC | Jonathan BillerGeneral Counsel | Sell Plan | 945 | $486.35 | $460K | +3.5% | — |
| Feb 26SEC | Edward Morrow Atkinson IIIEvp, Chief Technical Ops. Off. | Sell Plan | 668 | $486.35 | $325K | +3.5% | — |
| Feb 26SEC | Mark E. BunnageEvp, Chief Scientific Officer | Sell Plan | 620 | $486.35 | $302K | +3.5% | — |
| Feb 26SEC | Ourania TatsisEvp, Chief Reg. & Quality Off. | Sell Plan | 260 | $486.35 | $126K | +3.5% | — |
| Feb 26SEC | Kristen AmbroseSvp & Chief Accounting Officer | Sell Plan | 223 | $486.35 | $108K | +3.5% | — |
| Feb 23SEC | Amit SachdevEvp Chief Patient & Ext Af Off | Sell Plan | 19,662 | $468.57 | $9.2M | +7.5% | — |
| Feb 23SEC | Amit SachdevEvp Chief Patient & Ext Af Off | Sell Plan | 11,712 | $470.54 | $5.5M | +7.0% | — |
| Feb 23SEC | Amit SachdevEvp Chief Patient & Ext Af Off | Sell Plan | 10,263 | $467.75 | $4.8M | +7.6% | — |
| Feb 23SEC | Amit SachdevEvp Chief Patient & Ext Af Off | Sell Plan | 7,241 | $469.61 | $3.4M | +7.2% | — |
| Feb 23SEC | Amit SachdevEvp Chief Patient & Ext Af Off | Sell Plan | 4,237 | $471.43 | $2.0M | +6.8% | — |
| Feb 23SEC | Amit SachdevEvp Chief Patient & Ext Af Off | Sell Plan | 2,730 | $465.05 | $1.3M | +8.3% | — |
| Feb 23SEC | Amit SachdevEvp Chief Patient & Ext Af Off | Sell Plan | 1,848 | $465.80 | $861K | +8.1% | — |
| Feb 23SEC | Amit SachdevEvp Chief Patient & Ext Af Off | Sell Plan | 920 | $463.91 | $427K | +8.5% | — |
| Feb 19SEC | Jonathan BillerGeneral Counsel | Sell Plan | 2,476 | $489.46 | $1.2M | +2.9% | — |
| Feb 19SEC | Mark E. BunnageEvp, Chief Scientific Officer | Sell Plan | 2,437 | $489.46 | $1.2M | +2.9% | — |
| Feb 19SEC | Edward Morrow Atkinson IIIEvp, Chief Technical Ops. Off. | Sell Plan | 2,031 | $489.46 | $994K | +2.9% | — |
| Feb 19SEC | Kristen AmbroseSvp & Chief Accounting Officer | Sell Plan | 1,557 | $489.46 | $762K | +2.9% | — |
| Feb 19SEC | Jonathan BillerGeneral Counsel | Sell Plan | 1,244 | $473.68 | $589K | +6.3% | — |
| Feb 19SEC | Mark E. BunnageEvp, Chief Scientific Officer | Sell Plan | 1,182 | $473.68 | $560K | +6.3% | — |
| Feb 19SEC | Edward Morrow Atkinson IIIEvp, Chief Technical Ops. Off. | Sell Plan | 817 | $473.68 | $387K | +6.3% | — |
| Feb 19SEC | Kristen AmbroseSvp & Chief Accounting Officer | Sell Plan | 638 | $473.68 | $302K | +6.3% | — |
| Feb 19SEC | Ourania TatsisEvp, Chief Reg. & Quality Off. | Sell Plan | 609 | $489.46 | $298K | +2.9% | — |
| Feb 19SEC | Ourania TatsisEvp, Chief Reg. & Quality Off. | Sell Plan | 368 | $473.68 | $174K | +6.3% | — |
| Feb 18SEC | Ourania TatsisEvp, Chief Reg. & Quality Off. | Sell Plan | 1,500 | $499.99 | $750K | +0.7% | — |
| Feb 18SEC | Jonathan BillerGeneral Counsel | Sell Plan | 988 | $499.00 | $493K | +0.9% | — |
| Feb 18SEC | Sangeeta N. BhatiaDirector | Sell Plan | 266 | $500.00 | $133K | +0.7% | — |
| Feb 12SEC | Mark E. BunnageEvp, Chief Scientific Officer | Sell Plan | 2,021 | $460.43 | $931K | +9.4% | — |
| Feb 12SEC | Jonathan BillerGeneral Counsel | Sell Plan | 1,925 | $460.43 | $886K | +9.4% | — |
| Feb 12SEC | Edward Morrow Atkinson IIIEvp, Chief Technical Ops. Off. | Sell Plan | 1,751 | $460.43 | $806K | +9.4% | — |
| Feb 12SEC | Kristen AmbroseSvp & Chief Accounting Officer | Sell Plan | 1,376 | $460.43 | $634K | +9.4% | — |
| Feb 12SEC | Ourania TatsisEvp, Chief Reg. & Quality Off. | Sell Plan | 466 | $460.43 | $215K | +9.4% | — |
| Jan 9SEC | Ourania TatsisEvp, Chief Reg. & Quality Off. | Sell Plan | 4,500 | $474.99 | $2.1M | +6.0% | — |
| Jan 8SEC | Charles F Wagner Jr.Evp, Co & Fo | Sell Plan | 9,532 | $461.00 | $4.4M | +9.2% | — |
| Dec 5SEC | Jeffrey M LeidenChair | Sell Plan | 15,681 | $452.20 | $7.1M | +11.3% | — |
| Dec 5SEC | Jeffrey M LeidenChair | Sell Plan | 10,360 | $453.34 | $4.7M | +11.1% | — |
| Dec 5SEC | Jeffrey M LeidenChair | Sell Plan | 7,899 | $445.56 | $3.5M | +13.0% | — |
| Dec 5SEC | Charles F Wagner Jr.Evp, Co & Fo | Sell Plan | 7,000 | $461.00 | $3.2M | +9.2% | — |
| Dec 5SEC | Charles F Wagner Jr.Evp, Co & Fo | Sell Plan | 7,000 | $451.00 | $3.2M | +11.6% | — |
| Dec 5SEC | Jeffrey M LeidenChair | Sell Plan | 5,880 | $449.84 | $2.6M | +11.9% | — |
| Dec 5SEC | Jeffrey M LeidenChair | Sell Plan | 5,809 | $451.20 | $2.6M | +11.6% | — |
| Dec 5SEC | Ourania TatsisEvp, Chief Reg. & Quality Off. | Sell Plan | 4,500 | $449.99 | $2.0M | +11.9% | — |
| Dec 5SEC | Jeffrey M LeidenChair | Sell Plan | 4,469 | $440.40 | $2.0M | +14.3% | — |
| Dec 5SEC | Jeffrey M LeidenChair | Sell Plan | 4,352 | $444.36 | $1.9M | +13.3% | — |
| Dec 5SEC | Jeffrey M LeidenChair | Sell Plan | 2,469 | $443.21 | $1.1M | +13.6% | — |
| Dec 5SEC | Jeffrey M LeidenChair | Sell Plan | 2,320 | $448.78 | $1.0M | +12.2% | — |
| Dec 5SEC | Jeffrey M LeidenChair | Sell Plan | 2,070 | $455.22 | $942K | +10.6% | — |
| Dec 5SEC | Jeffrey M LeidenChair | Sell Plan | 1,320 | $441.26 | $582K | +14.1% | — |
| Dec 5SEC | Jeffrey M LeidenChair | Sell Plan | 1,152 | $447.05 | $515K | +12.6% | — |
| Dec 5SEC | Jonathan BillerGeneral Counsel | Sell Plan | 347 | $449.00 | $156K | +12.1% | — |
| Nov 19SEC | Edward Morrow Atkinson IIIEvp, Chief Technical Ops. Off. | Sell Plan | 2,500 | $434.58 | $1.1M | +15.9% | — |
| Nov 17SEC | Jeffrey M LeidenChair | Sell Plan | 32,234 | $440.30 | $14.2M | +14.4% | — |
| Nov 17SEC | Jeffrey M LeidenChair | Sell Plan | 21,330 | $441.35 | $9.4M | +14.1% | — |
| Nov 17SEC | Jeffrey M LeidenChair | Sell Plan | 18,528 | $440.22 | $8.2M | +14.4% | — |
| Nov 17SEC | Jeffrey M LeidenChair | Sell Plan | 1,160 | $441.05 | $512K | +14.2% | — |
| Nov 17SEC | Jeffrey M LeidenChair | Sell Plan | 40 | $442.00 | $18K | +13.9% | — |
Insiders at Vertex Pharmaceuticals
| Insider | Bought | Sold | Last filing | Score |
|---|---|---|---|---|
| Jeffrey M LeidenChair | — | $60.9M | Feb 26, 2026 | — |
| Amit SachdevEvp Chief Patient & Ext Af Off | — | $28.4M | Jul 23, 2026 | — |
| Reshma KewalramaniCEO, President | — | $19.7M | Mar 3, 2026 | — |
| Carmen BozicEvp And Cmo | — | $11.3M | Jun 30, 2026 | — |
| Charles F Wagner Jr.Evp, Co & Fo | — | $10.8M | Feb 26, 2026 | — |
| Ourania TatsisEvp, Chief Reg. & Quality Off. | — | $6.5M | Jul 23, 2026 | — |
| Duncan MckechnieEvp, Chief Commercial Officer | — | $5.7M | Jul 7, 2026 | — |
| Jonathan BillerGeneral Counsel | — | $3.8M | Feb 26, 2026 | — |
| Edward Morrow Atkinson IIIEvp, Chief Technical Ops. Off. | — | $3.6M | Feb 26, 2026 | — |
| Mark E. BunnageEvp, Chief Scientific Officer | — | $3.0M | May 19, 2026 | — |
| Joy LiuGeneral Counsel | — | $2.1M | Jul 6, 2026 | — |
| Kristen AmbroseSvp & Chief Accounting Officer | — | $2.0M | Sep 1, 2026 | — |
| Sangeeta N. BhatiaDirector | — | $268K | May 5, 2026 | — |
| Grunsven Jasper VanEvp, Cp And Nppo | — | — | Sep 10, 2026 | — |
| Bruce I SachsDirector | — | — | Aug 31, 2026 | — |
| Alan M GarberDirector | — | — | May 5, 2026 | — |
| Diana MckenzieDirector | — | — | May 5, 2026 | — |
| Jennifer SchneiderDirector | — | — | May 5, 2026 | — |
| Nancy ThornberryDirector | — | — | May 5, 2026 | — |
| Suketu UpadhyayDirector | — | — | May 5, 2026 | — |
| David AltshulerEvp, Chief Scientific Officer | — | — | Jan 26, 2026 | — |
| Lloyd CarneyDirector | — | — | Nov 20, 2025 | — |
Insider activity at other Health Care companies
Same sector, ranked by insider buying in the last 90 days.
Common questions about VRTX insiders
Are Vertex Pharmaceuticals insiders buying VRTX stock?
In the past 12 months, 0 insiders reported open-market purchases of VRTX worth $0.
Are Vertex Pharmaceuticals insiders selling VRTX stock?
13 insiders reported sales worth $158M over the same period.
Where does this data come from?
Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.